Macrophage-directed cardiovascular nanomedicines: Linking pharmaceutical design with cell state, lesion niche, and intracellular function

Macrophages coordinate inflammation, clearance, repair, and remodeling in cardiovascular disease, but these functions vary with disease stage, tissue location, ontogeny, and intracellular stress. Consequently, bulk macrophage uptake is a weak surrogate for therapeutic precision. This review examines how pharmaceutical design can be aligned with macrophage state, lesion niche, and the intracellular processes that a treatment is intended to modify. We compare delivery constraints in atherosclerosis, myocardial infarction and ischemia-reperfusion injury, post-infarction remodeling, and device- or graft-associated inflammation. The discussion examines circulation, clearance by the mononuclear phagocyte system, lesion access, cell recognition, stimulus-responsive activation, intracellular trafficking, and drug action within organelles. At each stage, we identify the evidence needed to support common targeting claims, including ligand accessibility after plasma exposure, state-selective uptake, compartment-specific release, mechanism-linked potency, and cardiovascular outcomes. We also consider human target confirmation, pharmacokinetics, repeated-dose immune safety, manufacturability, and critical quality attributes. Evaluation of macrophage-directed formulations should therefore link formulation properties to defined biological mechanisms and clinically relevant outcomes, rather than rely on uptake or colocalization alone.